TF
TVTX icon

Talbot Financial’s Travere Therapeutics TVTX Stock Holding History

Talbot Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-63,546
Closed -$12.9M – 66
2024
Q2 		$12.9M Buy
+63,546
New +$428K 1.67% 22

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Talbot Financial's TVTX Position: Q3 2024 in Review

Talbot Financial sold out of Travere Therapeutics (TVTX) in Q3 2024, closing a stake of 63,546 shares — an estimated $12.9M sold.

Talbot Financial first reported a position in TVTX in Q2 2024 and held it in 1 quarter. The position peaked at $12.9M in Q2 2024. 178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

  • Talbot Financial reported no remaining Travere Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Talbot Financial sold 63,546 Travere Therapeutics shares in Q3 2024, an estimated $12.9M.
  • Talbot Financial first reported a position in Travere Therapeutics in Q2 2024 and held it in 1 quarter.
  • Talbot Financial's Travere Therapeutics position peaked at $12.9M in Q2 2024.
  • 178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Talbot Financial's 13F filing for Q3 2024, filed 8 Oct 2024.